Cargando…

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Most patients with diffuse large B-cell lymphoma (DLBCL) can be cured with immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients with progression or relapse in the central nervous system (CNS) face dismal outcomes. The impact of more aggr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thieblemont, Catherine, Altmann, Bettina, Frontzek, Fabian, Renaud, Loïc, Chartier, Loic, Ketterer, Nicolas, Récher, Christian, Poeschel, Viola, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Morschhauser, Franck, Glass, Bertram, Mounier, Nicolas, Tilly, Herve, Rosenwald, Andreas, Ott, German, Lenz, Georg, Molina, Thierry, Ziepert, Marita, Schmitz, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410133/ https://www.ncbi.nlm.nih.gov/pubmed/36716220 http://dx.doi.org/10.1182/bloodadvances.2022008888

Ejemplares similares

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
por: Busson, Raphaël, et al.
Publicado: (2019)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
por: Bonnet, Christophe, et al.
Publicado: (2022)

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
por: Al Tabaa, Yassine, et al.
Publicado: (2023)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.
por: Cartron, G., et al.
Publicado: (2022)

Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
por: Paunescu, Alexandra-Cristina, et al.
Publicado: (2021)

Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
por: Paunescu, Alexandra‑Cristina, et al.
Publicado: (2021)

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial
por: Camus, Vincent, et al.
Publicado: (2022)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020)

Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)
por: Zettl, Florian, et al.
Publicado: (2020)

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
por: Aubrais, Raphaelle, et al.
Publicado: (2022)

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
por: Hohloch, Karin, et al.
Publicado: (2014)

New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT
por: Cottereau, Anne-Ségolène, et al.
Publicado: (2021)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY
por: Loyaux, Romain, et al.
Publicado: (2023)

Evolution of Matrix Gla and Bone Gla Protein Genes in Jawed Vertebrates
por: Leurs, Nicolas, et al.
Publicado: (2021)

Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
por: Kühnl, A., et al.
Publicado: (2017)

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022)

(18)F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
por: Girum, Kibrom B., et al.
Publicado: (2022)

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years
por: Jullien, Maxime, et al.
Publicado: (2021)

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
por: Thieblemont, Catherine, et al.
Publicado: (2019)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
por: Braulke, Friederike, et al.
Publicado: (2022)

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
por: Ghesquières, Hervé, et al.
Publicado: (2021)

Yeast Derived LysA2 Can Control Bacterial Contamination in Ethanol Fermentation
por: Kim, Jun-Seob, et al.
Publicado: (2018)

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

A Second Endolysin Gene Is Fully Embedded In-Frame with the lysA Gene of Mycobacteriophage Ms6
por: Catalão, Maria João, et al.
Publicado: (2011)

Development of Phage Lysin LysA2 for Use in Improved Purity Assays for Live Biotherapeutic Products
por: Dreher-Lesnick, Sheila M., et al.
Publicado: (2015)

KMWin – A Convenient Tool for Graphical Presentation of Results from Kaplan-Meier Survival Time Analysis
por: Gross, Arnd, et al.
Publicado: (2012)

P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY
por: Renaud, L., et al.
Publicado: (2022)

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas
por: Revailler, Wendy, et al.
Publicado: (2022)

Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein
por: Liabeuf, Sophie, et al.
Publicado: (2014)

Matrix Gla protein in tumoral pathology
por: GHEORGHE, SIMONA ROXANA, et al.
Publicado: (2016)

P1123: EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA: RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY
por: Delfau-Larue, Marie-Helene, et al.
Publicado: (2023)

Erratum: Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pfhib9q805kpgt6jb36jeplqne